Walter M. Stadler to Recombinant Fusion Proteins
This is a "connection" page, showing publications Walter M. Stadler has written about Recombinant Fusion Proteins.
Connection Strength
0.122
-
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.
Score: 0.081
-
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cells. Int J Oncol. 2000 Sep; 17(3):425-32.
Score: 0.041